S = selection of patients initiating semaglutide, tirzepatide, dulaglutide, or sitagliptin (as a placebo proxy) via propensity score 1:1 nearest neighbor matching to mimic randomization
While Health Canada doesn't give any further timeline as to when drugs might be approved, Mina Tadrous, associate professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto, says he estimates generics might be available by this summer or early fall
132, # 33, p
Tratamientos profesionales por caja
however, trim-and-fill imputed no missing studies, and the pooled estimate was unchanged (SMD 1.201, 95% CI 2.115 to 0.287)
Patients experiencing troublesome hot flushes should seek medical review to exclude alternative causes such as thyroid dysfunction or menopausal status